Clinical Trial Search

Primary: Number of Participants With Adverse Events for Self-administered Etripamil NS Outside of the Clinical Setting. — 324 Participants

Primary: A Composite of the Total Number of Participants With Either Tachycardia Change or Tachycardia Termination With First Ablation Set. — 38; 29 Participants

Primary: Change in Heart Rate — 17.0; 13.1 beats per minute

Primary: Number of Electrocardiograms (ECGs) Collected — 77; 67; 53 ECG

Primary: Total Fluoroscopy Time — 18.3; 7.5 minutes

Primary: The Percentage of Subjects Successfully Converted From PSVT to Sinus Rhythm Within 15 Minutes of Study Drug Administration — 20; 15; 20; 13 Participants — p=<0.05

Primary: Number of Participants With Freedom From Device-and Procedure-related Adverse Events and Serious Adverse Events — 71; 14; 85; 83 Participants

Primary: Change in Premature Atrial Contractions (PACs) — -0.6; -5.6 Episodes/hour

Primary: Number of Participants With Recurrent Atrial Fibrillation — 60; 31 Participants

Primary: Chronic Effectiveness (Through 6 Months) of the Freezor Xtra Catheter for the Treatment of AVNRT Using an Endocardial Approach. — 368; 29 Participants — p=<0.0001

Primary: 24hr Urinary Sodium — 16.8; 280; 14.7; 245 milliequivalents

Primary: Termination of SVT — 16; 21 participants

Primary: Number of Subjects With Operative and Post-operative Serious Adverse Events — 4; 1 participants

Primary: Incidence of Recurrent Supraventricular Tachycardia (SVT) Requiring Medical Intervention to Terminate the Episode. — 12; 18 percentage of participants

Primary: Number of Participants With Device or Procedure-related Serious Adverse Events — 12; 2 Participants